Please ensure Javascript is enabled for purposes of website accessibility

California's Cannabis Tax Revenues Top $1 Billion

By David Jagielski - Mar 11, 2020 at 11:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been just over two years since legal recreational marijuana sales started in the Golden State.

The cannabis market in California has generated more than $1 billion in revenue for the state since January 2018, when adults were first able to legally buy pot there for recreational use. Prior to full legalization, the California Legislative Analyst's Office, which is tasked with advising the legislature on policy and fiscal issues, estimated that at its peak, the cannabis industry could generate $1 billion in tax revenues annually in the state. 

For comparison, Colorado hit a total of $1 billion in tax revenue from pot sales only last year, after legal cannabis had been available for more than five years. 

California's strong results come despite the fact that pot sales by illicit dealers still account for approximately 75% of the total in the state. And there's concern that the growth in the legal market is stalling. In the fourth quarter of 2019, legal pot sales increased by just 1.5% from the prior quarter. That was the smallest quarterly growth rate since pot sales began -- revenue has typically grown by more than 15%. 

Marijuana store sign.

Image source: Getty Images.

California market still very attractive for pot producers

Curaleaf (CURLF -2.87%) is among the bigger cannabis companies operating in the California market after its acquisition of Cura Partners, which owned Select -- a popular cannabis brand on the West Coast. In Curaleaf's last reported quarter, sales were up 189% year over year to $61.8 million. And factoring in its pending acquisitions, pro forma revenue was more than double that at $129 million. 

Unfortunately, amid layoffs and a lot of instability in the cannabis industry of late, Curaleaf's stock price has slid. Over the past six months, its shares are down more than 40%. However, that's still significantly better than the performance of the Horizons Marijuana Life Sciences ETF (HMLSF 3.29%), which tracks the North American Medical Marijuana Index. That ETF is down by about 60% over the same period.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizons Marijuana Life Sciences Index ETF Stock Quote
Horizons Marijuana Life Sciences Index ETF
$2.81 (3.29%) $0.09
Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
$5.07 (-2.87%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.